RECHERCHE :   Tumeurs solides avancées
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
Amgen 20210023: A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
Advanced MTAP-null solid tumors
I, II
HUG
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
II
HUG
CA099-003: A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
Advanced Solid Tumors
I, II
HUG
FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
Solid Tumors with FGFR2b Overexpression
I, II
HUG
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
I
CHUV
INCB 123667-101: A phase I, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Histologically or citologically confirmed advanced or metastatic solid tumors
I
CHUV
MK-0472 A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 asMonotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Advanced/Metastatic Solid Tumors with RTK-driven mutations
I
HUG
MK6598-001 : A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumors
I
HUG
MK7339-002 : A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
II
HUG
PH- IL12L19L19-01/19: A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Advanced or metastatic carcinomas and diffuse large B-cell lymphoma
I
HUG
T3P1001: An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours
Tumeurs solides de stade avancé
I, II
CHUV
TAK-676-1002: An open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-676 as single agent and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors
Part 2: Histologically confirmed metastatic or unresectable recurrent SCCHN considered incurable by local therapies (oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, paranasal sinues) - Part 3: Histologically confirmed recurrent locally advanced or metastatic MSI-H/dMMR or MSS/pMMR CRC
I
CHUV, HUG